Replies to post #546731 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks

It is an important point to keep in mind that Liau has specifically stated that FDA mandated crossover for trial participants suffering from GBM. Most recently, she confirmed it during the JAMA interview that Dr. Low published here on iHub—I was so happy to hear her confirm this fact again … brain surgeons are always so precise and accurate it seems, and we need that kind of clarity amid all the noise.

Skip to timestamp 8:01. Dr. Liau again confirms that the crossover was mandated by the FDA.
https://edhub.ama-assn.org/jn-learning/audio-player/18738384



https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

[SkyLimit2022]

Thanks for posting.

The Keytruda trial is different. This trial is intriguing because it uses no chemo, no radiation, and there is no mandatory crossover design. Crossover is not required because 100% of the placebo control group are receiving murcidencel.

https://clinicaltrials.gov/ct2/show/NCT04201873








Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40